Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research
Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
18 affiliations
- 1Department of Internal Medicine , National Taiwan University Hospital , Taipei City ;
- 2Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , ;
- 3Department of Thoracic Oncology , Cancer Center , West China Hospital , Sichuan University , Chengdu , ;
- 4Fudan University Shanghai Cancer Center , Shanghai , ;
- 5Samsung Medical Center , Sungkyunkwan University School of Medicine , Seoul , ;
- 6Kurume University School of Medicine , Kurume , ;
- 7Shizuoka Cancer Center , Nagaizumi , ;
- 8Department of Medicine , Universiti Malaya , Kuala Lumpur , ;
- 9Department of Internal Medicine , College of Medicine , National Cheng Kung University , Tainan ;
- 10Tata Medical Center , Kolkata , ;
- 11Department of Clinical Oncology , School of Clinical Medicine , LKS Faculty of Medicine , The University of Hong Kong , , ;
- 12Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty , Istanbul , ;
- 13Artemis Hospital , Gurugram , Haryana , ;
- 14Division of Hematology and Medical Oncology , Department of Internal Medicine , Seoul National University Bundang Hospital , Seoul National University College of Medicine , Seongnam , ;
- 15Johnson & Johnson , Raritan , NJ , ;
- 16Johnson & Johnson , Spring House , PA , ;
- 17Johnson & Johnson , Titusville , NJ , ;
- 18Division of Medical Oncology , Yonsei Cancer Center , Yonsei University College of Medicine , Seoul ,
Related
- Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
- Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
- DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report
- EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report
- Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
BibTeX
@article{shih2026amivantamab,
title = {{Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup}},
author = {Jin-Yuan Shih and Jie Wang and Yongsheng Wang and Jialei Wang and Se-Hoon Lee and Koichi Azuma and Toshiaki Takahashi and Jiunn-Liang Tan and Chien-Chung Lin and Sandip Ganguly and Victor Ho-Fun Lee and Zeynep Hande Turna and Richu Sharma and Yu Jung Kim and Pei-Ling Chu and Sujay Shah and Brooke Diorio and Byoung Chul Cho},
journal = {Translational Lung Cancer Research},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13657905},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
AU - Jin-Yuan Shih
AU - Jie Wang
AU - Yongsheng Wang
AU - Jialei Wang
AU - Se-Hoon Lee
AU - Koichi Azuma
AU - Toshiaki Takahashi
AU - Jiunn-Liang Tan
AU - Chien-Chung Lin
AU - Sandip Ganguly
AU - Victor Ho-Fun Lee
AU - Zeynep Hande Turna
AU - Richu Sharma
AU - Yu Jung Kim
AU - Pei-Ling Chu
AU - Sujay Shah
AU - Brooke Diorio
AU - Byoung Chul Cho
PY - 2026
DA - 2026/09/24
JO - Translational Lung Cancer Research
UR - https://europepmc.org/article/PMC/PMC13657905
SN - 2218-6751
ER -